{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T05:42:03Z","timestamp":1782970923793,"version":"3.54.5"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006752","name":"Universidade do Porto","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006752","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Aqueous suppressants (AS) are commonly used after glaucoma drainage device (GDD) surgery to limit early rises in intraocular pressure (IOP). This review aims to evaluate whether the timing or regimen of postoperative aqueous suppression influences IOP control, the hypertensive phase (HP) incidence, surgical success, postoperative complications and visual outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic review of PubMed, Scopus, and Web of Science was conducted. Studies evaluating postoperative AS initiation after GDD surgery were included. Studies involving combined procedures, except clear-cornea phacoemulsification, were excluded.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Seven studies were included: three randomized clinical trials (RCT), three retrospective cohort studies, and one case series. All studies involved exclusively Ahmed glaucoma valve (AGV) implantation. Regarding timing, early AS initiation was evaluated in five studies and was associated with a significantly lower HP incidence in two of them. Despite heterogeneous definitions of surgical success and failure, three studies showed either higher success rates or lower failure rates compared with delayed initiation. Only one RCT demonstrated consistently lower IOP values across all follow-up visits up to 1 year. In a paediatric RCT, prolonged aqueous suppression resulted in lower IOP and reduced hyperencapsulation at 1 year. Regarding IOP-lowering drug class, one study found that AS achieved better IOP control, reduced long-term need for glaucoma medications, and higher success rates compared with prostaglandin analogues. Earlier initiation did not increase the rates of hypotony or major complications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Early AS initiation after AGV implantation is associated with lower HP incidence in several studies, but the certainty of evidence is low to moderate and long-term benefit remains uncertain.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00417-026-07367-1","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T04:28:35Z","timestamp":1782966515000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Initial aqueous suppressant therapy after glaucoma drainage device implantation: a systematic review"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-1264-5723","authenticated-orcid":false,"given":"Ana Carlota","family":"Silva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6503-9270","authenticated-orcid":false,"given":"David","family":"Alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7816-816X","authenticated-orcid":false,"given":"Jo\u00e3o","family":"Barbosa-Breda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,2]]},"reference":[{"key":"7367_CR1","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1016\/j.ophtha.2014.05.013","volume":"121","author":"Y-C Tham","year":"2014","unstructured":"Tham Y-C, Li X, Wong TY et al (2014) Global prevalence of glaucoma and projections of glaucoma burden through 2040. Ophthalmology 121:2081\u20132090. https:\/\/doi.org\/10.1016\/j.ophtha.2014.05.013","journal-title":"Ophthalmology"},{"key":"7367_CR2","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1001\/archopht.120.10.1268","volume":"120","author":"A Heijl","year":"2002","unstructured":"Heijl A, Leske M, Bengtsson B (2002) Reduction of intraocular pressure and glaucoma progression: results from the early manifest glaucoma trial. Arch Ophthalmol 120:1268\u20131279. https:\/\/doi.org\/10.1001\/archopht.120.10.1268","journal-title":"Arch Ophthalmol"},{"key":"7367_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/bjophthalmol-2025-egsguidelines","volume":"109","author":"M Pazos","year":"2025","unstructured":"Pazos M, Traverso CE, Viswanathan A (2025) European Glaucoma Society \u2013 terminology and guidelines for glaucoma, 6th edition. Br J Ophthalmol 109:1\u2013212. https:\/\/doi.org\/10.1136\/bjophthalmol-2025-egsguidelines","journal-title":"Br J Ophthalmol"},{"key":"7367_CR4","doi-asserted-by":"publisher","first-page":"CD004399","DOI":"10.1002\/14651858.CD004399.pub3","volume":"2012","author":"J Burr","year":"2012","unstructured":"Burr J, Azuara-Blanco A, Avenell A, Tuulonen A (2012) Medical versus surgical interventions for open angle glaucoma. Cochrane Database Syst Rev 2012:CD004399. https:\/\/doi.org\/10.1002\/14651858.CD004399.pub3","journal-title":"Cochrane Database Syst Rev"},{"key":"7367_CR5","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.ajo.2011.10.026","volume":"153","author":"SJ Gedde","year":"2012","unstructured":"Gedde SJ, Schiffman JC, Feuer WJ et al (2012) Treatment outcomes in the Tube Versus Trabeculectomy (TVT) study after five years of follow-up. Am J Ophthalmol 153:789\u2013803e2. https:\/\/doi.org\/10.1016\/j.ajo.2011.10.026","journal-title":"Am J Ophthalmol"},{"key":"7367_CR6","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1097\/IJG.0000000000001011","volume":"27","author":"J Barbosa-Breda","year":"2018","unstructured":"Barbosa-Breda J, Gon\u00e7alves-Pinho M, Santos JV et al (2018) Trends in glaucoma surgical procedures in Portugal: A 16-year nationwide study (2000\u20132015). J Glaucoma 27:682\u2013686. https:\/\/doi.org\/10.1097\/IJG.0000000000001011","journal-title":"J Glaucoma"},{"key":"7367_CR7","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1097\/01.icu.0000193080.55240.7e","volume":"17","author":"KS Schwartz","year":"2006","unstructured":"Schwartz KS, Lee RK, Gedde SJ (2006) Glaucoma drainage implants: a critical comparison of types. Curr Opin Ophthalmol 17:181\u2013189. https:\/\/doi.org\/10.1097\/01.icu.0000193080.55240.7e","journal-title":"Curr Opin Ophthalmol"},{"key":"7367_CR8","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1016\/S0002-9394(03)00630-5","volume":"136","author":"K Nouri-Mahdavi","year":"2003","unstructured":"Nouri-Mahdavi K, Caprioli J (2003) Evaluation of the hypertensive phase after insertion of the Ahmed glaucoma valve. Am J Ophthalmol 136:1001\u20131008. https:\/\/doi.org\/10.1016\/S0002-9394(03)00630-5","journal-title":"Am J Ophthalmol"},{"key":"7367_CR9","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.ajo.2017.01.003","volume":"176","author":"PG Christakis","year":"2017","unstructured":"Christakis PG, Zhang D, Budenz DL et al (2017) Five-year pooled data analysis of the Ahmed Baerveldt comparison study and the Ahmed versus Baerveldt Study. Am J Ophthalmol 176:118\u2013126. https:\/\/doi.org\/10.1016\/j.ajo.2017.01.003","journal-title":"Am J Ophthalmol"},{"key":"7367_CR10","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.survophthal.2018.10.008","volume":"64","author":"RA Fargione","year":"2019","unstructured":"Fargione RA, Tansuebchueasai N, Lee R, Tania Tai TY (2019) Etiology and management of the hypertensive phase in glaucoma drainage-device surgery. Surv Ophthalmol 64:217\u2013224. https:\/\/doi.org\/10.1016\/j.survophthal.2018.10.008","journal-title":"Surv Ophthalmol"},{"key":"7367_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-41790-1","volume":"9","author":"KI Jung","year":"2019","unstructured":"Jung KI, Woo JE, Park CK (2019) Effects of aqueous suppressants and prostaglandin analogues on early wound healing after glaucoma implant surgery. Sci Rep 9:5251. https:\/\/doi.org\/10.1038\/s41598-019-41790-1","journal-title":"Sci Rep"},{"key":"7367_CR12","doi-asserted-by":"publisher","first-page":"4851","DOI":"10.1167\/iovs.13-12274","volume":"54","author":"J Freedman","year":"2013","unstructured":"Freedman J, Iserovich P (2013) Pro-inflammatory cytokines in glaucomatous aqueous and encysted Molteno implant blebs and their relationship to pressure. Invest Ophthalmol Vis Sci 54:4851\u20134855. https:\/\/doi.org\/10.1167\/iovs.13-12274","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"7367_CR13","first-page":"881","volume":"50","author":"AC Molteno","year":"1976","unstructured":"Molteno AC, Straughan JL, Ancker E (1976) Control of bleb fibrosis after glaucoma surgery by anti-inflammatory agents. S Afr Med J 50:881\u2013885","journal-title":"S Afr Med J"},{"key":"7367_CR14","doi-asserted-by":"publisher","first-page":"2868","DOI":"10.2353\/ajpath.2010.090914","volume":"176","author":"M Zenkel","year":"2010","unstructured":"Zenkel M, Lewczuk P, J\u00fcnemann A et al (2010) Proinflammatory cytokines are involved in the initiation of the abnormal matrix process in pseudoexfoliation syndrome\/glaucoma. Am J Pathol 176:2868\u20132879. https:\/\/doi.org\/10.2353\/ajpath.2010.090914","journal-title":"Am J Pathol"},{"key":"7367_CR15","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1097\/00061198-200210000-00006","volume":"11","author":"D-N Hu","year":"2002","unstructured":"Hu D-N, Ritch R, Liebmann J et al (2002) Vascular endothelial growth factor is increased in aqueous humor of glaucomatous eyes. J Glaucoma 11:406\u2013410. https:\/\/doi.org\/10.1097\/00061198-200210000-00006","journal-title":"J Glaucoma"},{"key":"7367_CR16","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1097\/00061198-199400330-00011","volume":"3","author":"RC Tripathi","year":"1994","unstructured":"Tripathi RC, Borisuth NS, Li J, Tripathi BJ (1994) Growth factors in the aqueous humor and their clinical significance. J Glaucoma 3:248\u2013258","journal-title":"J Glaucoma"},{"key":"7367_CR17","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1097\/00005768-199904000-00006","volume":"31","author":"GM Gehlsen","year":"1999","unstructured":"Gehlsen GM, Ganion LR, Helfst R (1999) Fibroblast responses to variation in soft tissue mobilization pressure. Med Sci Sports Exerc 31:531\u2013535. https:\/\/doi.org\/10.1097\/00005768-199904000-00006","journal-title":"Med Sci Sports Exerc"},{"key":"7367_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijsu.2021.105906","volume":"88","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Int J Surg 88:105906. https:\/\/doi.org\/10.1016\/j.ijsu.2021.105906","journal-title":"Int J Surg"},{"key":"7367_CR19","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"J Higgins","year":"2024","unstructured":"Higgins J, Thomas J, Chandler J (2024) Cochrane Handbook for Systematic Reviews of Interventions, 6.5. Cochrane","edition":"6.5"},{"key":"7367_CR20","unstructured":"National Institutes of Health (2021) Study Quality Assessment Tools. https:\/\/www.nhlbi.nih.gov\/health-topics\/study-quality-assessment-tools"},{"key":"7367_CR21","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1097\/IJG.0000000000000131","volume":"25","author":"SK Law","year":"2016","unstructured":"Law SK, Kornmann HL, Giaconi JA et al (2016) Early aqueous suppressant therapy on hypertensive phase following glaucoma drainage device procedure: a randomized prospective trial. J Glaucoma 25:248\u2013257. https:\/\/doi.org\/10.1097\/IJG.0000000000000131","journal-title":"J Glaucoma"},{"key":"7367_CR22","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1016\/j.ophtha.2014.03.014","volume":"121","author":"M Pakravan","year":"2014","unstructured":"Pakravan M, Rad SS, Yazdani S et al (2014) Effect of early treatment with aqueous suppressants on Ahmed glaucoma valve implantation outcomes. Ophthalmology 121:1693\u20131698. https:\/\/doi.org\/10.1016\/j.ophtha.2014.03.014","journal-title":"Ophthalmology"},{"key":"7367_CR23","doi-asserted-by":"publisher","first-page":"e101","DOI":"10.1111\/aos.14220","volume":"98","author":"MF Rateb","year":"2020","unstructured":"Rateb MF, Eldaly ZH, Soliman WM (2020) Early weaning versus prolonged administration of aqueous suppressants for prevention of hyperencapsulation in paediatric Ahmed glaucoma valve. Acta Ophthalmol 98:e101\u2013e106. https:\/\/doi.org\/10.1111\/aos.14220","journal-title":"Acta Ophthalmol"},{"key":"7367_CR24","doi-asserted-by":"publisher","first-page":"416","DOI":"10.3390\/jcm9020416","volume":"9","author":"J Lee","year":"2020","unstructured":"Lee J, Park CK, Jung KI (2020) Initial glaucoma medication in the hypertensive phase following Ahmed valve implantation: a comparison of results achieved using aqueous suppressants and prostaglandin analogs. J Clin Med 9:416. https:\/\/doi.org\/10.3390\/jcm9020416","journal-title":"J Clin Med"},{"key":"7367_CR25","doi-asserted-by":"publisher","first-page":"167","DOI":"10.4103\/joco.joco_244_21","volume":"34","author":"R Saha","year":"2022","unstructured":"Saha R, Dharia RS, Trope GE, Buys YM (2022) Effect of prophylactic aqueous suppression on Ahmed glaucoma valve surgery success. J Curr Ophthalmol 34:167\u2013172. https:\/\/doi.org\/10.4103\/joco.joco_244_21","journal-title":"J Curr Ophthalmol"},{"key":"7367_CR26","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.ogla.2023.08.002","volume":"7","author":"M Tang","year":"2024","unstructured":"Tang M, Gill NP, Tanna AP (2024) Effect of early aqueous suppression after valved tube shunt surgery for uveitic glaucoma. Ophthalmol Glaucoma 7:37\u201346. https:\/\/doi.org\/10.1016\/j.ogla.2023.08.002","journal-title":"Ophthalmol Glaucoma"},{"key":"7367_CR27","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.ogla.2023.08.001","volume":"7","author":"WS Shalaby","year":"2024","unstructured":"Shalaby WS, Wong J-C, Zhang TZ et al (2024) Early postoperative aqueous suppression therapy and surgical outcomes of Ahmed tube shunts in refractory glaucoma. Ophthalmol Glaucoma 7:47\u201353. https:\/\/doi.org\/10.1016\/j.ogla.2023.08.001","journal-title":"Ophthalmol Glaucoma"},{"key":"7367_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-022-02493-w","volume":"22","author":"YK Kang","year":"2022","unstructured":"Kang YK, Shin JP, Kim DW (2022) Long-term surgical outcomes of Ahmed valve implantation in refractory glaucoma according to the type of glaucoma. BMC Ophthalmol 22:270. https:\/\/doi.org\/10.1186\/s12886-022-02493-w","journal-title":"BMC Ophthalmol"},{"key":"7367_CR29","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1016\/j.ophtha.2007.10.031","volume":"115","author":"J Caprioli","year":"2008","unstructured":"Caprioli J, Coleman AL (2008) Intraocular pressure fluctuation: a risk factor for visual field progression at low intraocular pressures in the advanced glaucoma intervention study. Ophthalmology 115:1123-1129e.e3. https:\/\/doi.org\/10.1016\/j.ophtha.2007.10.031","journal-title":"Ophthalmology"},{"key":"7367_CR30","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1001\/archophthalmol.2011.72","volume":"129","author":"CGV De Moraes","year":"2010","unstructured":"De Moraes CGV (2010) Risk factors for visual field progression in treated glaucoma. Arch Ophthalmol 129:562\u2013568. https:\/\/doi.org\/10.1001\/archophthalmol.2011.72","journal-title":"Arch Ophthalmol"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-026-07367-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00417-026-07367-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-026-07367-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T04:28:42Z","timestamp":1782966522000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00417-026-07367-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,2]]},"references-count":30,"alternative-id":["7367"],"URL":"https:\/\/doi.org\/10.1007\/s00417-026-07367-1","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,2]]},"assertion":[{"value":"4 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable, as no new studies with human participants or animals were conducted by the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable, as no new studies with human participants were conducted by the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}